Seroprevalence of anti Vi antibodies and immunogenicity of Typhim Vi vaccine in children

Human Vaccines

Volumn 4, Issue 4, 2008, Pages 305-308

  Gupta, Divya ^a   Faridi, M M A ^a   Aggarwal, Anju ^a   Kaur, Iqbal ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Anti Vi antibodies; Immunogenicity; Safety; Typhim Vi vaccine

Indexed keywords

BACTERIUM ANTIBODY; TYPHOID VACCINE; VI ANTIBODY;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SEIZURE; SEROCONVERSION; SEROPREVALENCE; TYPHOID FEVER; UNCONSCIOUSNESS;

EID: 50849106089     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.4.5824     Document Type: Article

References (14)

1. Crump JA, Luby SD, Mintz ED. The global burden of typhoid fever. Bull World Health Org 2004; 82:346-53.
2. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354:734-7.
3. Saha MR, Dutta P, Palit A, Dutta D, Bhattacharya MK, Mitra U, et al. A note on incidence of Typhoid fever in diverse age group in Kolkata, India. Jpn J Infect Dis 2003; 56:121-2.
4. Yaph LC, Rivera RC, Disp AP, Mallabo J. Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years. Biodrugs 2001; 15:27.
5. Acharya IL, Lowe CU, Thapa R, Gumbacharya VL, Shrestha MB, Cadoz M, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Typhi: A preliminary report. New Engl J Med 1987; 317:1101-4.
6. Panchnathan V, Kumar S, Yeap W, Devi S, Ismail R, Sarijan S, et al. Comparison of safety and immungenecity of Vi polysaccharide typhoid vaccine with whole cell vaccine in Malaysian air force recruits. Bull World Health Org 2001; 79:811-7.
7. Mirza NB, Wakmola IA, Estambale BA, Mbithbi E, Poillet M. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. East Afr Med J 1995; 72:162-4.
8. Azze RF, Rodriguez JC, Iniesta MG, Marchena YR, Alfonso VM, Padron FT. Immunogenicity of New S. Typhi Vi polysaccharide vaccine - Vax Ty - Vi in Cuban school children and teenagers. Vaccine 2003 Jun 20; 21:2758-60.
9. Arnold WSG, Harcus AW, St Clair Roberts J, Wrad AE. Experience with Vi typhoid capsular polysaccharide vaccine in the UK. J Infect 1992; 25:63-6.
10. Musher DM, Groover JE, Watson DA, Pandey JP, Rodriguez Barradas MC, Baughn RE, et al. Generic regulation of the capacity to make immunoglobulin G to pneumonococcal capsular polysaccharides. J Invest Med 1997; 45:57-68.
11. Dizer U, Gorenek L, Guner O, Pehlivan T, Ozguven V, Pahsa A, et al. Assessment of antibody response in 110 healthy individuals who have been subjected to Vi capsular polysaccharide vaccine. Vaccine 2002; 20:3052-4.
12. Kietal WA, Bond WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12:195-9.
13. Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schutz D, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 2:1165-9.
14. Yang HH, Wu CG, Yie GZ, Gu QW, Wang BR, Wang LY, et al. Efficacy trial of Vi capsular polysaccharide vaccine against typhoid fever in South-West China. Bull World Health Org 2001; 79:625-31.